Recent Updates
Recently added Catalysts
IPHA Positive Sentiment

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Innate Pharma announced plans to initiate the TELLOMAK-3 Phase 3 study of lacutamab for cutaneous T-cell lymphoma, pending the completion of a partnership with Sobi. Additionally, Markus Jensen has been appointed as the new Chief Medical Officer, effective September 1, 2026, succeeding the previous officer. This strategic move aims to bolster the company's leadership and research efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Innate Pharma is advancing lacutamab to Phase 3 trials.
  • The partnership with Sobi is a strategic move for the company.
  • Appointment of a new Chief Medical Officer strengthens leadership.

Full Press Release Details

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding So

Frequently Asked Questions

What is the TELLOMAK-3 study?

The TELLOMAK-3 study is a confirmatory Phase 3 trial for lacutamab in CTCL.

Who is the new Chief Medical Officer at Innate Pharma?

Markus Jensen has been appointed as the new Chief Medical Officer.

What is the focus of the lacutamab study?

The lacutamab study focuses on treating cutaneous T-cell lymphoma.

When will the new CMO start at Innate Pharma?

Markus Jensen will start as CMO on September 1, 2026.

What is the significance of the partnership with Sobi?

The partnership with Sobi is strategic for advancing lacutamab's development.

ShareAdd on Google
Tags: IPHA Viatris Investor Conferences Healthcare Innate Pharma lacutamab Phase 3 cutaneous T-cell lymphoma Sobi
Last updated: Aug 10, 2026

Biotech snapshot

Lead asset
IPH4502Phase 1
Advanced or Metastatic Solid Tumors →